The region’s blossoming technology sector is about to get another shot of financial fertilizer. The newly formed Allos Ventures has raised $20 million from investors and plans to focus on early-stage ...

CAMBRIDGE, Mass., Aug. 21, 2025 /PRNewswire/ -- Allos Pharma Inc., announces key milestones advancing its mission to deliver effective treatments for Autism Spectrum Disorder (ASD), Fragile X Syndrome ...

Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma (rrPTCL). A ...

Allos Ventures makes investing in early-stage companies look easy. National data shows it is not. According to a 2018 Harvard Business School study, 75 percent of venture-backed startups fail. So one ...

Novel use of Causal AI revives long-stalled development pathways across complex generics and next-generation medicines for chronic disease Allos bends the cost-risk curve of drug development and ...

AMAG Pharmaceuticals, Inc. /quotes/zigman/107237/quotes/nls/amag AMAG +3.59% and Allos Therapeutics, Inc. /quotes/zigman/81880/quotes/nls/alth ALTH +17.48% today ...

Allos Ventures, an Indianapolis-based venture capital firm, will continue its buy in on the Midwest with the $52 million close of its latest fund, Allos III. That investment, leadership said, will ...

TEL AVIV (MarketWatch) -- Allos Therapeutics Inc., the Westminster, Colo., biopharma focused on cancer drugs, agreed to be acquired by Spectrum Pharmaceuticals Inc. for $1.82 cash plus a contigent ...

BANGALORE, Sept 25 (Reuters) - Allos Therapeutics said U.S. health regulators granted accelerated approval for its drug Folotyn to treat one of the most deadly and aggressive types of white blood cell ...

Allos S/A Ord Allos SA operates and manages shopping centers. It provides services that range from planning and development of a project up to structural, financial, leasing, legal, and operational ...